Thymosin Beta-4

Thymosin Beta-4 (TB-4) is a naturally occurring 43-amino acid peptide originally isolated from the thymus gland. It functions primarily as an actin-sequestering protein, meaning it binds to actin monomers, preventing their polymerization into actin filaments. This action plays a crucial role in various cellular processes, including cell migration, wound healing, angiogenesis (blood vessel formation), and inflammation modulation. While TB-4 is naturally produced in the body, synthetic versions are available and have become the subject of research and, controversially, unregulated consumer use.

The mechanism of action of TB-4 extends beyond simple actin sequestration. Research suggests it can also upregulate the production of extracellular matrix components, reduce inflammation by modulating cytokine release, and promote cell survival through various signaling pathways. For example, a study published in the *World Journal of Gastroenterology* found that TB-4 released by mast cells under stress conditions can impair the intestinal epithelial barrier via IL22RA1/JAK1/STAT3 signaling in irritable bowel syndrome, highlighting a complex and context-dependent role.

The research landscape surrounding TB-4 is broad, with over 1100 research papers published on the topic. These studies investigate its potential therapeutic applications in diverse areas, including wound healing, cardiovascular disease, neurological disorders, and ophthalmology. ClinicalTrials.gov lists 21 clinical trials involving TB-4. While some trials, such as a Phase 4 study investigating its use in preventing early mortality in presumptive tuberculosis treatment, have been terminated, others have reached Phase 3. Notably, ReGenTree, LLC has sponsored several Phase 3 trials (ARISE-2, ARISE-3, and SEER-2) assessing the safety and efficacy of RGN-259, an ophthalmic solution containing TB-4, for the treatment of dry eye syndrome and neurotrophic keratitis. AstraZeneca also completed a Phase 3 trial examining the use of Symbicort, which contains TB-4, for the treatment of persistent asthma. However, it's important to note that the presence of TB-4 in Symbicort is not the primary active ingredient, which is a combination of a corticosteroid and a long-acting beta2-agonist.

The safety profile of TB-4 is still under investigation. While some studies suggest it is well-tolerated, the FDA adverse event reporting system has recorded a small number of reports (2 total) associated with TB-4 use. These reports, none of which were classified as serious, included reactions such as increased blood potassium, drug ineffectiveness, elevated hepatic enzymes, hypertension, and impaired gastric emptying. It is crucial to acknowledge that these reports do not establish a causal relationship between TB-4 and the reported adverse events, but they warrant further scrutiny.

The regulatory status of TB-4 is complex. It is not FDA-approved for any indication and is currently categorized as a Category 2 substance, meaning it is banned from compounding by pharmacies. This classification stems from concerns regarding its potential safety and efficacy when prepared in non-FDA-regulated compounding facilities. Despite this, TB-4 remains unregulated in many other contexts, leading to its availability through various online vendors and its use by individuals seeking purported benefits related to healing, muscle growth, and joint health.

The use of TB-4 is prevalent among athletes and bodybuilders who believe it accelerates recovery from injuries and promotes muscle growth. Others use it for its purported anti-inflammatory and wound-healing properties. However, it is vital to emphasize that these uses are largely based on anecdotal evidence and preliminary research, and the long-term safety and efficacy of TB-4 in these contexts remain uncertain. The current regulatory landscape and ongoing research suggest that the understanding and regulation of Thymosin Beta-4 will continue to evolve.